Literature DB >> 9347614

The GluR2 (GluR-B) hypothesis: Ca(2+)-permeable AMPA receptors in neurological disorders.

D E Pellegrini-Giampietro1, J A Gorter, M V Bennett, R S Zukin.   

Abstract

The abnormal influx of Ca2+ through glutamate receptor channels is thought to contribute to the loss of neurons associated with a number of brain disorders. Until recently, the NMDA receptor was the only glutamate receptor known to be Ca(2+)-permeable. It is now well established that AMPA receptors exist not only in Ca(2+)-impermeable but also in Ca(2+)-permeable forms. AMPA receptors are encoded by four genes designated gluR1 (gluR-A) through gluR4 (gluR-D). The presence of the gluR2 subunit renders heteromeric AMPA receptor assemblies Ca(2+)-impermeable. Recent studies involving animal models of transient forebrain ischemia and epilepsy show that gluR2 mRNA is downregulated in vulnerable neurons. These observations suggest that downregulation of gluR2 gene expression may serve as a 'molecular switch' leading to the formation of Ca(2+)-permeable AMPA receptors and enhanced toxicity of endogenous glutamate following a neurological insult.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9347614     DOI: 10.1016/s0166-2236(97)01100-4

Source DB:  PubMed          Journal:  Trends Neurosci        ISSN: 0166-2236            Impact factor:   13.837


  134 in total

1.  Voltage-dependent block of native AMPA receptor channels by dicationic compounds.

Authors:  D B Tikhonov; M V Samoilova; S L Buldakova; V E Gmiro; L G Magazanik
Journal:  Br J Pharmacol       Date:  2000-01       Impact factor: 8.739

Review 2.  Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment.

Authors:  Christine Konradi; Stephan Heckers
Journal:  Pharmacol Ther       Date:  2003-02       Impact factor: 12.310

3.  Neuroprotective potential of ionotropic glutamate receptor antagonists.

Authors:  Wojciech Danysz; Chris G Parsons
Journal:  Neurotox Res       Date:  2002-03       Impact factor: 3.911

4.  Comparison of the anticonvulsive activities of organic mono- and dications with their abilities to inhibit NMDA and AMPA glutamate receptors.

Authors:  N Ya Lukomskaya; N I Rukoyatkina; L V Gorbunova; V E Gmiro; K V Bol'shakov; L G Magazanik
Journal:  Neurosci Behav Physiol       Date:  2004-02

Review 5.  The neurophysiology and pathology of brain zinc.

Authors:  Stefano L Sensi; Pierre Paoletti; Jae-Young Koh; Elias Aizenman; Ashley I Bush; Michal Hershfinkel
Journal:  J Neurosci       Date:  2011-11-09       Impact factor: 6.167

Review 6.  Bigenomic regulation of cytochrome c oxidase in neurons and the tight coupling between neuronal activity and energy metabolism.

Authors:  Margaret T T Wong-Riley
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

Review 7.  Febrile seizures: mechanisms and relationship to epilepsy.

Authors:  Céline M Dubé; Amy L Brewster; Tallie Z Baram
Journal:  Brain Dev       Date:  2009-02-15       Impact factor: 1.961

Review 8.  Brain vulnerability and viability after ischaemia.

Authors:  Stefano G Daniele; Georg Trummer; Konstantin A Hossmann; Zvonimir Vrselja; Christoph Benk; Kevin T Gobeske; Domagoj Damjanovic; David Andrijevic; Jan-Steffen Pooth; David Dellal; Friedhelm Beyersdorf; Nenad Sestan
Journal:  Nat Rev Neurosci       Date:  2021-07-21       Impact factor: 34.870

9.  AMPA receptor properties are modulated in the early stages following pilocarpine-induced status epilepticus.

Authors:  Isabella Russo; Daniela Bonini; Luca La Via; Sergio Barlati; Alessandro Barbon
Journal:  Neuromolecular Med       Date:  2013-03-15       Impact factor: 3.843

10.  Rebalance of striatal NMDA/AMPA receptor ratio underlies the reduced emergence of dyskinesia during D2-like dopamine agonist treatment in experimental Parkinson's disease.

Authors:  Vincenza Bagetta; Carmelo Sgobio; Valentina Pendolino; Giulia Del Papa; Alessandro Tozzi; Veronica Ghiglieri; Carmela Giampà; Elisa Zianni; Fabrizio Gardoni; Paolo Calabresi; Barbara Picconi
Journal:  J Neurosci       Date:  2012-12-05       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.